CTM · Codex 轨独立取证稿

Castellum, Inc. · NYSE American · CIK 0001877939 · 双轨中的 Codex 轨 r1 与 r2,全程未读对轨 · 2026-09-24

三格稿(r1)

CTM 话事人专项

双轨·Codex 轨 r1,独立取证,未读对轨。

取证基准日:2026-09-24。公司为 Castellum, Inc.,CIK 0001877939,财年止于 12-31,SIC 8742,内华达州注册,总部在 Vienna, VA,属于新兴成长公司;原件写明挂牌市场为 NYSE American LLC,而非元数据简称所示的 NYSE。〔10-K|2026-03-09|0001877939-26-000016〕

全量 submissions 的 formerNames 为空,最早一件为 2021-10-19 Form D,accession 0001877939-21-000002。〔SEC submissions|2026-09-24|CIK0001877939〕

三格

董事长

B. Champoux(2022-10-12起)

title:Bernard S. Champoux;现任独立董事长,接 Mark C. Fuller;历史起点存在原件内冲突,见下。

定性:他掌董事会议程与董事会—管理层沟通,但并非大股东。〔DEF 14A|2026-04-07|0001877939-26-000025〕

CEO

G. Ives(2024-07-01起)

title:Glen R. Ives;接 Mark C. Fuller;兼 President,2025-05-28 起兼董事。

定性:经营权由受雇 CEO 掌握,任期与激励由独立董事长代表公司续签。〔8-K|2026-07-02|0001877939-26-000057〕

资本话事人

J. Wright(2022-10-12转换起)

title:Jay O. Wright;2019-06-11 随 Bayberry 交易入场;2026-03-20 受益持股 9,383,838 股/自算个人分母 96,861,615 股=9.69%;现为最大已披露自然人持有人,但已无席位。本稿归类为被动资本锚,并判断公司无单一控股股东。〔DEF 14A|2026-04-07|0001877939-26-000025〕

定性:他仍是最大已披露投票块,却没有现行提名权、投资者权利协议或公司职务,不能单独拍板。〔DEF 14A|2026-04-07|0001877939-26-000025〕

一行版:董事长:Bernard S. Champoux|CEO:Glen R. Ives|资本话事人:Jay O. Wright。

为什么不是一个人说了算

全量提交索引与最新一件

2026-09-24 重新拉取的无表单过滤 submissions JSON 没有 files 溢出索引,recent 的 304 件就是全量;按该索引的新到旧顺序,首件为 2026-09-09 Form 4,accession 0001877939-26-000079,不是同日较早的 8-K 0001877939-26-000078。〔SEC submissions|2026-09-24|CIK0001877939〕

表单件数表单件数表单件数
10-K410-Q128-K/8-K/A97/1
Form 3/3/A13/1Form 4/4/A96/10Form 51
Form 1447SC 13D/13D/A2/0SC 13G1
424B2/424B4/424B51/2/8S-1/S-1/A1/4S-3/S-3/A3/1
S-83DEF 14A/DEFA14A4/4PRE 14C/DEF 14C1/1
8-A12B/CERT1/1D1EFFECT4
CORRESP/UPLOAD10/6DRS/DRS/A/DRSLTR1/1/1合计304

注:brief 所称“S-1/S-1/A 四份”与全量索引不符;本轮重数为 S-1 一份、S-1/A 四份,合计五份。〔SEC submissions|2026-09-24|CIK0001877939〕

最新 Form 4 是 Chief Operating Officer Andrew Merriman 于 2026-09-09 的两笔公开市场买入:40,000 股、每股 $0.6193;10,000 股、每股 $0.62;交易后直接持有 588,531 股。〔Form 4|2026-09-09|0001877939-26-000079〕

截止日后补件

以本地 sec/official/CIK0001877939_submissions_2026-07-13.json 为旧截止,至 2026-09-24 共新增六件;本轮均按 archive index 下载主件、附件、全文提交件及索引至 kp/sec-new-codex/。〔SEC submissions|2026-09-24|CIK0001877939〕

申报日表单accession与控制权相关性
2026-07-318-K0001877939-26-000065业绩会日程,无席位、出资或控制变动。
2026-08-0610-Q0001877939-26-000070更新股本、权证与 Part II。
2026-08-078-K0001877939-26-000073二季度业绩公告,无控制变动。
2026-08-318-K0001877939-26-000075GTMR 合同 ceiling 增加,无控制变动。
2026-09-098-K0001877939-26-000078管理层参会公告,无控制变动。
2026-09-09Form 40001877939-26-000079Andrew Merriman 公开市场买入 50,000 股。

两位自然人同日各报一份 SC 13D、四年无修订:他们现在还持多少

Jay O. Wright

Mark C. Fuller

全量索引只有这两份 SC 13D,没有 SC 13D/A;所以“四年无修订”是表单事实,不代表持股没变,后续变化只能由 Form 4、Form 5、Form 144 与年度受益所有权表续接。〔SEC submissions|2026-09-24|CIK0001877939〕

多数票曾怎样直接批事

三份人事 8-K 不是同一个位子反复换

定期报告逐项核验

最新 10-K 全部项

项目本轮读到的硬信息
Item 1七次收购后形成政府技术服务平台;Bayberry 为会计收购方,MFSI 已出售,Merrison 已并入 Corvus 后注销。
Item 1A风险包括持续增发稀释、政府合同、人才与许可、并购整合;2026-03-06 的最大潜在稀释为 19,950,231 股。
Item 1B/1C无未解决 SEC staff comments;网络安全由管理层与董事会/Audit Committee 监督,未报告重大网络影响。
Item 2/3/4无自有不动产,仅有租赁设施;无重大未保险诉讼;Mine Safety 不适用。
Item 5/6普通股自 2022-10-13 在 NYSE American 交易;2026-03-06 已发行 94,612,750 股、约 179 名登记股东;无普通股股息;Item 6 保留。
Item 7/7A2025-12-31 年度营收 $52.866 百万、净亏损 $2.398 百万、期末现金 $14.885 百万、backlog $258.194 百万;利率风险主要来自现金,旧债已固定或偿清。
Item 8RSM US LLP 出具无保留意见;财务报表及 Notes 1—17 已读。
Item 9/9A与会计师无分歧;披露控制与内部控制有效,期内无重大变更;EGC 身份下无审计师内控鉴证。
Item 9B/9C董事、高管在 2025-12-31 年度没有采纳或终止 10b5-1 或非 10b5-1 计划;外国检查辖区披露不适用。
Item 10—14以 2026-04-07 DEF 14A 纳入董事、高管、薪酬、所有权、关联交易与审计费。
Item 15/16财报与附件索引齐列;无 Form 10-K Summary。

以上各行均据同一整份原件。〔10-K|2026-03-09|0001877939-26-000016〕

最新 10-Q 的股本与 Part I

Part II 翻到了什么

增发、股本与主要持有人

424B5 的八份文件中有两组“未定价稿+最终稿”,不能数成八轮;本轮按成交实质归为六次主要股权融资,另把 424B2 识别为转售登记。〔SEC submissions|2026-09-24|CIK0001877939〕

轮次形式与定价原件给出的发行后股本
2022-10 IPO公司售 1,350,000 股、每股 $2.00,毛额 $2,700,000;售股股东另售 150,000 股;超配最多 225,000 股。〔424B4|2022-10-14|0001575872-22-000980〕41,513,132 股;全额超配为 41,738,132 股。
2024-01 registered direct+private placement5,243,967 股普通股、每股 $0.32;3,193,534 份预付权证、每份 $0.319、余款 $0.001;毛额 $2,696,807;另配 8,437,501 份私募权证、行权价 $0.35。〔424B5|2024-01-29|0001628280-24-002399〕56,109,928 股,假设预付权证全数行权。
2024-12 第一轮9,473,700 股、每股 $0.38,毛额 $3,600,006。〔424B5|2024-12-23|0001628280-24-052349〕65,583,628 股。
2024-12 第二轮4,355,000 股、每股 $0.85,毛额 $3,701,750;2024-12-27 的 0001628280-24-052467 是同轮未定价稿。〔424B5|2024-12-30|0001628280-24-052531〕69,938,628 股。
2025-03 units4,500,000 单位、每单位 $1.00,每单位一股加一份行权价 $1.08、60 日期权证,毛额 $4,500,000。〔424B5|2025-03-17|0001628280-25-013083〕89,391,874 股,包含假设 4,500,000 份权证全数行权;仅交割普通股后的 2025-03-21 实数为 84,891,874 股。
2025-06 units4,166,667 单位、每单位 $1.20,每单位一股加一份行权价 $1.22、60 日期权证,毛额 $5,000,000.40。〔424B5|2025-06-12|0001213900-25-053929〕94,980,751 股,包含假设权证全数行权。

2024-04-18 的 424B2 只登记 Armistice 对 8,437,501 股私募权证底股的转售;公司不售股、不会收到转售款,只有现金行权才可能收到最多约 $2,953,000,因此不是新一轮融资。〔424B2|2024-04-18|0001628280-24-016798〕

权证四项机关

每轮后能硬取到的主要持有人快照

下表不把不同日期的分母混算;“最近硬快照”不是发行日即时占比。

融资后阶段原件股本/分母日最近硬快照
2022-10 IPO 后2022-10-12 已发行 41,513,132 股Jay O. Wright 报 10,775,506 股、24.9%,Mark C. Fuller 报 9,363,452 股、21.7%;两人各加 1,715,934 份权证后的自算个人分母均为 43,229,066 股。Wright 的脚注组件另有算术冲突,见前节。〔两份 SC 13D|2022-10-24|0001575872-22-001020、0001575872-22-001021〕
2024-01 融资后招股书假设预付权证全行权后 56,109,928 股2024-04-05 已发行 53,029,915 股;Jay O. Wright 11,659,578 股/自算分母 55,278,780 股=21.09%。Mark C. Fuller 的表列 9,912,524 股、脚注合计 9,911,524 股,自算分母同为 55,278,780 股,原件均显示 17.93%。Armistice 表列 6,389,002 股、9.89%,但其工具与持股上限披露不能复现一个相容分母,未取到可调和分母;待核 0001877939-24-000028 与 0001628280-24-016798。〔DEF 14A|2024-04-16|0001877939-24-000028〕
2024-12 两轮后各轮原件分别给 65,583,628 股、69,938,628 股未取到两次交割日同日主要股东表;待核最近后续表 0001877939-25-000037,不以它倒推交割日。
2025-03 融资后2025-03-21 已发行 84,891,874 股Jay O. Wright 11,772,538 股/自算分母 87,140,739 股=13.51%;Mark C. Fuller 9,362,524 股/同一自算分母=10.74%。Jean and Nathalie Ekobo 的表列普通股栏为 5,769,375 股,脚注含 Series A 转换后为 6,356,875 股;以自算分母 85,479,374 股得 7.44%。〔DEF 14A|2025-04-11|0001877939-25-000037〕
2025-06 融资及后续行权后2026-03-20 已发行 94,612,750 股Jay O. Wright 9,383,838 股/自算分母 96,861,615 股=9.69%;Mark C. Fuller 5,172,524 股/同一自算分母=5.34%。〔DEF 14A|2026-04-07|0001877939-26-000025〕
最新季度2026-08-05 已发行 94,781,286 股未取到同日主要股东表;待核下一份 DEF 14A,不能沿用 2026-03-20 百分比。〔10-Q|2026-08-06|0001877939-26-000070〕

Form 4、4/A 与 Form 144

accession申报人原件所写修正
0001575872-22-001221Emil Kaunitzpurchase(P),column 3。
0001575872-22-001224David T. Bellpurchase(P),column 3。
0001575872-22-001226Mark C. Fullerpurchase(P),column 3。
0001575872-22-001228Mark C. Fullerpurchase(P),column 3。
0001575872-22-001230Jay O. Wrightpurchase(P),column 3。
0001575872-22-001232Jay O. Wrightpurchase(P),column 3。
0001575872-22-001234Jay O. Wrightpurchase(P),原件写 column 3.2。
0001575872-22-001236Jay O. Wrightpurchase(P),column 3。
0001575872-22-001238Jay O. Wrightpurchase(P),column 3。
0001575872-22-001240Mark S. Alariepurchase(P),column 3。

反向拆股与分拆

拿不准而明确保留的点

人物史抽屉(r1)

CTM 人物史抽屉

双轨·Codex 轨 r1,独立取证,未读对轨。

取证基准日:2026-09-24。下列事实只取自本轮亲手读过的原件;公司披露、本人申报与本稿判断分开写。

【draw-block 1】董事长块 — Bernard S. Champoux

title:Bernard S. Champoux;独立董事长。

1.履历时间线

2.过往壳、交易、并购串与所获

3.班底

4.资金来源、持股工具与打法

5.地址、国籍与注册地

6.控制链一句脚注

控制链:股东选董事会→独立董事会由 Bernard S. Champoux 主持→董事会任免并考核 Glen R. Ives→经营层执行;其 2026-03-20 受益持股 409,537 股,占自算个人分母 94,917,750 股的一小部分,不足以构成资本控制。〔DEF 14A|2026-04-07|0001877939-26-000025〕

监管、前后案与买卖

【draw-block 2】CEO 块 — Glen R. Ives

title:Glen R. Ives;President、Chief Executive Officer、Director。

1.履历时间线

2.过往壳、交易、并购串与所获

3.班底

4.资金来源、持股工具与打法

5.地址、国籍与注册地

6.控制链一句脚注

控制链:董事会授权并由 Bernard S. Champoux 签约→Glen R. Ives 以 President、CEO 身份统筹经营→子公司与职能高管执行;其 2026-03-20 的 3,216,783 股受益持股占自算个人分母 97,641,917 股的 3.29%,不足以越过董事会形成单人控制。〔DEF 14A|2026-04-07|0001877939-26-000025;8-K 附件 10.1|2026-07-02|0001877939-26-000057〕

监管、前后案与买卖

【draw-block 3】资本话事人块 — Jay O. Wright

title:Jay O. Wright;最大已披露自然人持有人、前 Vice Chair 与法务高管,现无公司席位。

1.履历时间线

2.过往壳、交易、并购串与所获

3.班底

4.资金来源、持股工具与打法

5.地址、国籍与注册地

6.控制链一句脚注

控制链:Bayberry 交易/Series B 对价→Jay O. Wright 形成历史最大自然人持股→2025-12-31 退出全部席位与高管权→其 2026-03-20 受益持股为 9,383,838 股/自算个人分母 96,861,615 股=9.69%,不能单独任免董事或 CEO。〔SC 13D|2022-10-24|0001575872-22-001020;8-K|2025-12-09|0001877939-25-000126;DEF 14A|2026-04-07|0001877939-26-000025〕

监管、前后案与买卖

次要人物短条

Mark C. Fuller

Armistice Capital Master Fund Ltd.

Jean and Nathalie Ekobo

C. Thomas McMillen

John F. Campbell

ROUND2 互核答复(r2)

CTM ROUND2 互核答复

双轨·Codex轨 r2,独立回件,未读对轨

取证截止:2026-09-24

分歧1:董事长起算日

1.1 2022-10-12绑在哪个身份上

不同意“2022-10-12只绑董事任期”。 2023代理书把该日分别明确绑定于“董事任期起算”和“获任Chair”;2026代理书则保留董事的日粒度,而把Chair改写为月粒度。

1.2 月粒度与日粒度是不是同一件事

同意。 就Chair任命而言,两句均写Champoux获任Chair;2023代理书直接给出2022-10-12,2026代理书写in October 2022,是同一任命的不同粒度。取2022-10-12更贴近现有原件的最高粒度,不是拿董事任期倒推,因为2023代理书的“Board Leadership Structure”本身已把该日直接写进Chair任命句。accession:0001877939-23-000009、0001877939-26-000025。

1.3 Mark C. Fuller何时卸任Chair

不同意“原件没有给日期”。 2025代理书给了终止日:“He served as Chair of the Board, Chief Executive Officer, and President of the Company from June 11, 2019 until June 30, 2024.” 所在段落为“Proposal No. 1—Election of Directors—Mark C. Fuller”。accession:0001877939-25-000037。

2023代理书另写:“Mr. Fuller was appointed a director, Chair of the Board, Chief Executive Officer and President on June 11, 2019 in connection with the acquisition of Bayberry Capital, Inc.” accession:0001877939-23-000009。

未取到: 能调和下列两组原件的发行人解释——一组称Champoux于2022-10-12获任Chair,另一组称Fuller任Chair至2024-06-30。不得据其中一人的日期倒推或改写另一人。待核件:相关原件accession为0001877939-23-000009、0001877939-25-000037、0001877939-26-000025;同期2022-10-18 Form 8-K accession 0001575872-22-000989未写Chair交接。若发行人另有董事会决议或更正件,其accession未取到。

分歧2:Bernard S. Champoux受益所有权

不同意“409,537股=104,537股普通股+375,000份期权”。 375,000是三批期权的名义总数,不是计入受益所有权总数的期权数;表内实际计入305,000,另有70,000尚未归属且未计入。

2026代理书“Ownership of Common Stock—Directors and Officers”先规定口径:“In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options or warrants or issuable under convertible securities held by that person that are currently exercisable or exercisable within 60 days of the Beneficial Ownership Date are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of any other person.” accession:0001877939-26-000025。

脚注(4)原句整抄:“Shares owned include (i) 104,537 shares of common stock over which Mr. Champoux has sole dispositive and voting power, (ii) 25,000 stock options that are exercisable at $3.40 per share that are exercisable into 25,000 shares of common stock over which Mr. Champoux has sole dispositive and voting power, (iii) 250,000 stock options that are exercisable at $0.212 per share into 250,000 shares of common stock over which Mr. Champoux has sole dispositive and voting power, and (iv) 100,000 stock options that are exercisable at $1.19 per share into 100,000 shares of common stock, of which 30,000 have vested and 70,000 which vest over time over which Mr. Champoux has sole dispositive and voting power.” accession:0001877939-26-000025。

按表重算:104,537+25,000+250,000+30,000=409,537。计入的期权为305,000;375,000=25,000+250,000+100,000只是名义授予总量。表列总数已排除最后一批中“70,000 which vest over time”的部分。结论:Codex轨的104,537+305,000口径同意;把全部375,000加进409,537不同意。

分歧3:Jay O. Wright资本格

3.1 2022-10-12与Series B转换

不同意“Series B在2022-10-12转换”。 原件把2022-10-12写成承销协议日、注册声明生效日及SC 13D事件日;发行转换股发生在募股完成日2022-10-17。

转换后的原件报出数为:“the Reporting Person is the beneficial owner of 10,775,506 shares of the Issuer’s common stock representing approximately 24.9% of the 41,513,132 shares of the Issuer’s common stock currently issued and outstanding.” 该件签署日原句为“Dated: October 24, 2022”。accession:0001575872-22-001020。

分母须保留原件内部差异:公司已发行基数报41,513,132;若依同件所报1,715,934份可行权权证作个人加回,个人分母为43,229,066,10,775,506÷43,229,066=24.93%,与报出24.9%相合。但该件脚注又原文报“(i) 9,842,252 common shares and (ii) 1,715,934 warrants”,两项相加并不等于10,775,506。此处只列原件冲突,不替其补洞。accession:0001575872-22-001020。

3.2 “转换起”是否进入格值

同意不把“转换起”放进格值。 一是“凭什么”应放可见title;二是原格把转换错系于2022-10-12。建议格值改为:

Jay O. Wright(2022-10-12起)

这里的2022-10-12只按SC 13D明确报出的“Date of Event which Requires Filing of this Statement”使用;title必须另写Series B转换股实际发行日为2022-10-17。accession:0001575872-22-001020、0001575872-22-000989。

3.3 2025-12-31离任后怎样写

同意“持股+席位”组合于2025-12-31日终解体;不同意把其后直接定性为“纯被动持股”。 Form 8-K原句为:“Jay O. Wright resigned his positions as Executive Vice-President Strategy, General Counsel, and Secretary, as well as a member of the Board of Directors of Castellum, Inc. (the ‘Company’), effective at the end of day on December 31, 2025.” 下一句为“There was no dispute between Mr. Wright and the Company.” accession:0001877939-25-000126。

2026代理书又写:“Mr. Wright resigned his positions as a director, Vice Chair of the Board, Executive Vice-President Strategy, General Counsel, and Secretary effective December 31, 2025.” accession:0001877939-26-000025。

其后原件只足以说他被列作“5% Stockholders”。2026代理书表列“Jay O. Wright (10) 9,383,838 9.69%”,脚注原句为:“Mr. Wright may be deemed to be the beneficial owner of 9,383,838 shares of the Company's common stock. Shares owned include (i) 7,134,973 shares of common stock over which Mr. Wright has sole dispositive and voting power and (ii) 2,248,865 warrants that are exercisable into 2,248,865 shares of common stock over which Mr. Wright has sole dispositive and voting power.” accession:0001877939-26-000025。

因此资本格可继续以SC 13D事件日2022-10-12起算,因为持股角色没有在离任日终止;但title应分段写清:2022-10-12为13D事件日;2022-10-17完成转换;席位至2025-12-31,其后仅列5%股东。 “纯被动”涉及原件没有给出的意图或法律状态,不写。

分歧4:Wright百分比分母

不同意把94,612,750直接标成Wright的百分比个人分母;同意它是公司已发行基数。 两轨只有在把94,612,750称为“公司基数”、再给Wright加回其可行权权证时,数学才一致。

2026代理书原句为:“Percentage of beneficial ownership is based on 94,612,750 shares of common stock outstanding as of the Beneficial Ownership Date.” 同段把“Beneficial Ownership Date”定义为March 20, 2026。accession:0001877939-26-000025。

同件的个人加回规则原句为:“In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options or warrants or issuable under convertible securities held by that person that are currently exercisable or exercisable within 60 days of the Beneficial Ownership Date are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of any other person.” accession:0001877939-26-000025。

报出数为表列“Jay O. Wright (10) 9,383,838 9.69%”;脚注(10)报7,134,973股普通股及2,248,865份可行权权证。accession:0001877939-26-000025。

重算:94,612,750+2,248,865=96,861,615;9,383,838÷96,861,615=9.6871%,四舍五入为9.69%。若直接用94,612,750作分母则为9.9183%,不能得到报出数。

建议上站三段式:报出9.69%|个人分母96,861,615股(公司基数94,612,750股+其可行权权证2,248,865份)|2026-03-20。accession:0001877939-26-000025。

共同项A:前用名

同意四段名称链;同意把EDGAR元数据空值写成“元数据失效例证”,但必须与原件事实分层。

S-1/A“Corporate History, Business Acquisitions and Other Information”原句为:“The Company was incorporated in Nevada on September 30, 2010 under the name Passionate Pet, Inc. and in January 2013 the Company changed its name to Firstin Wireless Technology, Inc. In March 2015 the Company changed its name to BioNovelus, Inc.” accession:0001575872-22-000944。

同段原句为:“On December 26, 2019, following our acquisition of Corvus, we changed our name from BioNovelus, Inc. to Castellum, Inc.” accession:0001575872-22-000944。

Form D结构化原件写<previousName>Bionovelus, Inc.</previousName>,同时写<edgarPreviousNameList><value>None</value></edgarPreviousNameList>。accession:0001877939-21-000002。此处保留原件拼法Bionovelus, Inc.,不擅改为S-1/A的BioNovelus, Inc.。

2026-09-24下载的公司submissions元数据为"formerNames":[]。该JSON快照本身不是一份带accession的申报件;历史事实仍只由上述S-1/A和Form D支撑。稿中可写:“EDGAR submissions元数据formerNames为空,但原件披露四段名称链;元数据不可替代逐件取证。”

共同项B:交易所

同意NYSE American,不同意只写NYSE。

Form 8-A登记栏原文为:“Title of each class to be so registered: Common stock, par value $0.0001 per share; Name of each exchange on which each class is to be registered: NYSE American LLC.” 同件另写:“The Common Stock is expected to be listed on the NYSE American LLC.” accession:0001575872-22-000931。

CERT提交件的原始文档说明为<DESCRIPTION>NYSE AMERICAN CERTIFICATION。accession:0001143313-22-000059。

2025-12-09 Form 8-K封面登记栏原文为:“Common stock, par value $0.0001 per share CTM NYSE American LLC.” accession:0001877939-25-000126。

因此站内名称应为NYSE American;submissions元数据的"exchanges":["NYSE"]只能列作元数据待核,不覆盖申报原件。

共同项C:两份SC 13D、零修订及Mark C. Fuller现况

C.1 Item 6有没有联合申报协议或一致行动安排

同意:两份Item 6都没有联合申报协议或一致行动安排。

Jay O. Wright件的Item 6原句为:“Except as disclosed herein, the Reporting Person does not have any contract, arrangement, understanding, or relationship with respect to securities of the Issuer including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. The Reporting Person has not pledged securities of the Issuer nor are the securities of the Issuer held by the Reporting Person subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities.” Item 7为“None.” accession:0001575872-22-001020。

Mark C. Fuller件的Item 6原句为:“Except as disclosed herein, the Reporting Person does not have any contract, arrangement, understanding, or relationship with respect to securities of the Issuer including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. The Reporting Person has not pledged securities of the Issuer nor are the securities of the Issuer held by the Reporting Person subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities.” Item 7为“None.” accession:0001575872-22-001021。

C.2 近四年没有SC 13D/A意味着什么

不同意“四年”这一精确表述;同意截至取证日未见SC 13D/A。 两份SC 13D均提交于2022-10-24;截至2026-09-24是3年11个月,不足整四年。两名自然人的全量个人提交索引中各只有上述一份SC 13D,没有SC 13D/A。起点accession:Jay O. Wright为0001575872-22-001020,Mark C. Fuller为0001575872-22-001021;索引端点所见各自最新申报为Jay O. Wright的2025-12-22 Form 4 accession 0001310272-25-000026、Mark C. Fuller的2025-09-03 Form 4 accession 0001944544-25-000014。

这里只陈述“原始SC 13D后至2026-09-24未见SC 13D/A”,不判断是否产生修订义务,也不下法律结论。

C.3 Mark C. Fuller现持多少、卸任CEO后是否仍在董事会

同意以最新受益所有权表报5,172,524股受益所有权;同时保留此前最新Form 4的不同时间点数值。

2025-09-03 Form 4的“Shares Owned Following Transaction”为6,113,659;脚注原句为:“Includes (a) 6,047,519 common shares held by The Mark Chappelle Fuller Revocable Trust, Mark Fuller, TTEE, (b) 50,000 common shares held by Janice Lynn Dudley Revocable Trust, Janice Lynn Dudley TTEE, and (c) 16,140 common shares held by Mark Fuller.” accession:0001944544-25-000014。

2026代理书截至2026-03-20表列Mark C. Fuller为5,172,524股、5.34%。脚注(9)原句为:“Mr. Fuller may be deemed to be the beneficial owner of 5,172,524 shares of common stock, which total is comprised of (i) 2,873,659 shares of common stock held by The Mark Chappelle Fuller Revocable Trust, Mark Fuller, TTEE, of which Mr. Fuller is the trustee and over which he has sole dispositive and voting power, (ii) 50,000 shares of common stock held by Janice Lynn Dudley Revocable Trust, Janice Lynn Dudley, TTEE, of which Ms. Dudley is the trustee and over which Ms. Dudley has sole dispositive and voting power, and (v) 2,248,865 warrants that are exercisable into 2,248,865 shares of the Company’s common stock over which Mr. Fuller has sole dispositive and voting power.” accession:0001877939-26-000025。

同意:他卸任CEO后仍继续任董事一段时间。 2025代理书原句为:“He served as Chair of the Board, Chief Executive Officer, and President of the Company from June 11, 2019 until June 30, 2024.” accession:0001877939-25-000037。其2025-09-03 Form 4脚注又明确:“Effective May 28, 2025, Mr. Fuller ceased to be a member of the Company's board of directors.” accession:0001944544-25-000014。因此其CEO任期止于2024-06-30,自2024-07-01不再任CEO,但董事身份延续至2025-05-28才终止。

r2结论

  1. 董事长格可取日粒度2022-10-12,但必须并列披露Fuller任Chair至2024-06-30的原件冲突,不能自行调和。
  2. Bernard S. Champoux的409,537股应拆为104,537股普通股+305,000份计入口径的期权;70,000份未归属期权不计入。
  3. Wright的2022-10-12是SC 13D事件日及注册生效日,不是Series B转换股发行日;转换股发行日为2022-10-17。
  4. Wright离任后仍是最新表中的最大5%自然人股东,但原件不足以称“纯被动持股”;格值保留2022-10-12起,身份变化写入title。
  5. Wright的9.69%对应个人分母96,861,615股;94,612,750股是公司已发行基数。

回 CTM 总入口 · 另一条轨 · 档案库首页。Codex 轨独立取证,未读对轨。KPClaude(yara)· 2026-09-24。研究记录,不构成投资建议。